Intravenous dexmedetomidine versus tramadol for treatment of shivering after spinal anesthesia: a meta-analysis of randomized controlled trials

Jinguo Wang, Zaitang Wang, Junyan Liu and Na Wang

Abstract

Background: Shivering is a frequent complication after spinal anesthesia. Increasing studies have compared the effect of intravenous dexmedetomidine and intravenous tramadol on shivering after spinal anesthesia, hence we performed a meta-analysis of randomized controlled trials to compare dexmedetomidine with tramadol on the treatment of post-spinal anesthesia shivering.

Methods: PubMed, Embase, Cochrane library, Web of Science and Google Scholar were searched to find the eligible studies comparing the effect of dexmedetomidine and tramadol on the treatment of shivering after spinal anesthesia. Mean difference (MD) or risk ratio (RR) along with 95% confidence interval (CI) was used to analyze the outcomes. I² test was conducted to assess the heterogeneity of the included trials. We utilized Review Manager 5.3 to perform statistical analyses.

Results: Thirteen randomized controlled trials including 864 subjects were included. Dexmedetomidine had higher effective rate of shivering control (RR = 1.03; 95%CI [1.01, 1.06], P = 0.01, I² = 14%), shorter time to cease shivering (MD = -2.14; 95%CI [-2.79, -1.49], P < 0.00001, I² = 98%), lower recurrent rate of shivering (RR = 0.45; 95%CI [0.27, 0.73], P = 0.001, I² = 0%), lower incidences of nausea (RR = 0.10; 95%CI [0.05, 0.19], P < 0.00001, I² = 48%), and vomiting (RR = 0.13; 95%CI [0.06, 0.30], P < 0.00001, I² = 0%), compared with tramadol.

Conclusions: Dexmedetomidine is superior to tramadol for shivering treatment, due to higher effective rate of shivering control, earlier onset of action and lesser recurrence of shivering with higher incidence of sedation and lower incidences of nausea and vomiting. However, dexmedetomidine is also associated with higher incidences of hypotension and bradycardia than tramadol.

Keywords: Dexmedetomidine, Tramadol, Postanesthesia shivering, Meta-analysis
**Background**
Shivering is a common perioperative complication because of postanesthesia hypothermia [1]. Spinal anesthesia has impairment of shivering in the block area and greater heat loss than general anesthesia because of abnormal heat loss owing to vasodilation [2, 3]. Shivering can cause severe consequences, such as arterial hypoxia and myocardial ischemia by increasing oxygen consumption [4, 5]. Tramadol is commonly used for the treatment of shivering in clinical practice. However, tramadol can lead to nausea and vomiting which is very distressing for the patient. Therefore, it is necessary to find a better drug with fewer side effects. Dexmedetomidine, an alpha 2-adrenergic agonist, has been confirmed the effect on treatment and prevention of shivering in various surgeries by reducing the shivering threshold [6].

There are no large-sample clinical trials evaluating the advantages or disadvantages between dexmedetomidine and tramadol on post-spinal anesthesia shivering. Therefore, we conduct a meta-analysis of randomized controlled trials (RCTs) to compare the effect of intravenous dexmedetomidine and tramadol on post-spinal anesthesia shivering.

**Methods**
**Literature review**
Relevant articles were found by searching PubMed, Cochrane library, Web of Science and Google Scholar by two investigators independently. The terms used for searching included: “Dex”, “Dexmedetomidine”, “Tramadol”, “Anesthesia, Spinal”, “Injections, Spinal” and “Shivering” through March 2020, without limits. Furthermore,
| Author    | Date  | Dosage                                                                 | Study type | Jadad Score | Sample size D/T | Patient characteristics; Surgical setting                                                                 | Type of anesthesia; Drug for anesthesia                                                                 | Definition of shivering | Outcomes measures |
|-----------|-------|-------------------------------------------------------------------------|------------|-------------|----------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------|-------------------|
| Kundra    | 2017  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 5      | 5           | 50/50         | 18–65 yr, ASA: I-II; Orthopedic, general, or urological surgery                                          | Spinal anesthesia; 0.5% bupivacaine                              | Grade 3 or 4          | ☐☐☐☐☐☐☐☐☐☐ |
| Venkatraman | 2016  | Dexmedetomidine 0.5 μg/kg, tramadol 1 mg/kg                             | RCT 5      | 5           | 30/30         | 18–70 yr, ASA: I-II; No mention                                                                         | Spinal anesthesia; To achieve sensory level of at least T10     | Grades 2 to 4         | ☐☐☐☐☐☐☐☐☐☐ |
| Mittal    | 2014  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 25/25         | 18–65 yr, ASA: I-II; Lower abdominal, lower limb, orthopaedic and plastic surgeries                     | Spinal anesthesia; 0.5% heavy bupivacaine 15 mg                  | Grade 3 or 4          | ☐☐☐☐☐☐☐☐☐☐ |
| Fern      | 2015  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 3      | 5           | 20/20         | 18–70 yr, ASA: I-II; Elective orthopaedic, gynaecology or general surgery                               | Combined spinal and epidural anesthesia; 0.5% hyperbaric bupivacaine 15 mg | Grade 3 or 4          | ☐☐☐☐☐☐☐☐☐☐ |
| Keerthi   | 2017  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 32/32         | 18–60 yr, ASA: I-II; Lower abdomen and lower limb surgery                                               | Spinal anesthesia; 0.5% hyperbaric bupivacaine 2.8 to 3 ml      | Grades 2 to 4         | ☐☐☐☐☐☐☐☐☐☐ |
| Ramesh    | 2019  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 3      | 5           | 30/30         | 18–65 yr, ASA: I-II; Elective lower limb surgery                                                        | Spinal anesthesia; 0.5% hyperbaric bupivacaine 12.5 mg          | Grade 3 for at least 2 min | ☐☐☐☐☐☐☐☐☐☐ |
| Verma     | 2018  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 60/60         | 18–65 yr, ASA: I-II; Elective lower limb, lower abdominal, gynaecological procedures, caesarean sections | Spinal anesthesia; No mention                                    | Grade 3 or 4          | ☐☐☐☐☐☐☐☐☐☐ |
| Prasad    | 2018  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 5      | 5           | 25/25         | 18–40 yr, ASA: I-II; Caesarean section                                                                  | Spinal anesthesia; 0.5% hyperbaric bupivacaine                   | Grade 3 or 4          | ☐☐☐☐☐☐☐☐☐☐ |
| Kumar     | 2016  | Dexmedetomidine 0.6 μg/kg, tramadol 1.0 mg/kg                           | RCT 3      | 5           | 20/20         | 18–60 yr, ASA: I-II; Elective lower abdominal surgeries and lower limb surgeries                        | Spinal anesthesia; 0.5% hyperbaric bupivacaine 15 mg            | Grade 3               | ☐☐☐☐☐☐☐☐☐☐ |
| Verma     | 2016  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 30/30         | 18–45 yr, ASA: I-II; Elective abdominal, gynaecological and orthopedic surgeries                       | Spinal anesthesia; 0.5% hyperbaric bupivacaine 15 mg            | Grades 2 to 4         | ☐☐☐☐☐☐☐☐☐☐ |
| Singla    | 2017  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 50/50         | 18–65 yr, ASA: I-II; Various surgeries under spinal anesthesia                                         | Spinal anesthesia; 0.5% hyperbaric bupivacaine 3–36 ml          | Grades 2 to 4         | ☐☐☐☐☐☐☐☐☐☐ |
| Singh     | 2016  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 4      | 5           | 30/30         | 20–50 yr, ASA: I-II; Elective lower abdominal, lower limb orthopaedic and gynaecological surgeries     | Spinal anesthesia; 0.5% hyperbaric bupivacaine 15 mg            | Grade 3               | ☐☐☐☐☐☐☐☐☐☐ |
| Aasim     | 2016  | Dexmedetomidine 0.5 μg/kg, tramadol 0.5 mg/kg                           | RCT 5      | 5           | 30/30         | 18–65 yr, ASA: I-II; Various surgeries under spinal anesthesia                                         | Spinal anesthesia; 0.5% hyperbaric bupivacaine 15 mg            | Grade 3               | ☐☐☐☐☐☐☐☐☐☐ |

RCT: randomized controlled trial, ASA: American Society of Anesthesiologists, ①: Effective rate of shivering treatment, ②: Time to cease shivering, ③: recurrent rate of shivering, ④: the incidence of nausea, ⑤: the incidence of vomiting, ⑥: the incidence of bradycardia, ⑦: the incidence of hypotension, ⑧: sedation score
the researchers looked through the references of the relative papers to find additional studies.

**Inclusion criteria of studies**
Inclusion criteria were as follows: 1) the patients underwent an operation under spinal anesthesia or combined spinal and epidural anesthesia; 2) the comparison was between intravenous dexmedetomidine and tramadol about the treatment effect of shivering; 3) the incidence of side effects was reported in both dexmedetomidine and tramadol groups; 4) the study was a RCT. Meeting papers, correspondences and editorials were excluded.

**Data extraction**
Data were collected independently by two researchers, including patient characteristics, types of surgery, anesthetic type, the drugs for spinal anesthesia, doses of the study drugs, shivering degree, efficacy of shivering treatment, incidence of recurrent shivering and adverse effects. Shivering was graded using a four point scale as per Wrench in all included papers [7]. Any disaccord was further settled by the third researcher.

**Evaluation of risk of bias and the study quality**
Two researchers independently evaluated the risk of bias and the qualities of all included studies according to Cochrane Handbook v5.0.2 and 5 point Jadad scale [8]. Each of the following items of risk of bias was graded as “high risk of bias”, “uncertain risk of bias” or “low risk of bias”: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Disputes were settled by discussion, if necessary, a third investigator helped to make a decision.

**Statistical analysis**
Review Manager 5.3 (Cochrane Collaboration, Copenhagen, Denmark) was utilized to perform all statistical analyses. For dichotomous data, risk ratio (RR) with 95% confidence interval (CI) was calculated with the Mantel-Haenszel method. Mean difference was used for continuous variables. If there was significant heterogeneity ($I^2 > 50\%$), we tried to find possible reasons of heterogeneity, and then sensitivity analysis was performed with fixed effect model.

**Results**
Figure 1 showed the flow chart of this meta-analysis. Thirteen studies were included, involving 864 patients (432 received dexmedetomidine and 432 tramadol) [9–21]. The characteristics of the identified clinical trials were displayed in Tables 1. Surgeries were performed under spinal anesthesia in 12 studies [9–20] and under combined spinal and epidural anesthesia in one study [21]. In the included studies, 7 compared dexmedetomidine with tramadol [9–15] and the other 6 compared dexmedetomidine with tramadol and clonidine [16–18, 20], pethidine [21] or butorphanol [19]. Because our study only compared dexmedetomidine with tramadol, clonidine, pethidine and butorphanol were neglected. The risk-of-bias plot was formed utilizing Review Manager 5.3. (Fig. 2).
Effective rate

All eligible RCTs reported the effective rate of shivering control [9–21]. The value of $I^2 = 0\%$ indicated no heterogeneity among the included studies. Dexmedetomidine had higher effective rate of shivering control than tramadol (RR = 1.03; 95% CI [1.01, 1.06]; $P = 0.01$, $I^2 = 14\%$). (Fig. 3).

Time to cease shivering

Twelve included RCTs compared time to cease shivering of dexmedetomidine and tramadol [9–16, 18–21]. The random effect model was utilized, because a high heterogeneity was detected ($I^2 = 98\%$). The result showed that dexmedetomidine was associated with shorter time to cease shivering than tramadol (MD = -2.14; 95% CI [-2.79, -1.49]; $P < 0.00001$, $I^2 = 98\%$). (Fig. 4) Sensitivity analysis was performed for time to cease shivering by excluding single study sequentially, but no source of heterogeneity was detected.

Recurrent rate of shivering

There were 12 studies reporting the recurrent rate of shivering [9–20]. The value of $I^2 = 0\%$ indicated no heterogeneity. The result of this study indicated that the recurrent rate of shivering of tramadol was significantly higher than that of dexmedetomidine (RR = 0.45; 95%CI [0.27, 0.73]; $P = 0.001$, $I^2 = 0\%$). (Fig. 5).

Nausea and vomiting

Ten papers recorded nausea [9–13, 15, 18–21] and 10 recorded vomiting [9–13, 15, 16, 18–20]. Four out of

---

**Fig. 3** Forest plot for effective rate of shivering. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

**Fig. 4** Forest plot for time to cease shivering in minutes. Abbreviations: SD, standard deviation; CI, confidence interval; IV, inverse variance
332 patients receiving dexmedetomidine experienced nausea, and 80 out of 332 patients receiving tramadol experienced nausea. There were 342 patients receiving dexmedetomidine (1 with vomiting) and 342 patients receiving tramadol (41 with vomiting). Dexmedetomidine had lower incidences of nausea and vomiting than tramadol (Nausea: RR = 0.10; 95%CI [0.05, 0.19], \( P < 0.00001 \), \( I^2 = 48\% \); Vomiting: RR = 0.13; 95% CI [0.06, 0.30], \( P < 0.00001 \), \( I^2 = 0\% \)). (Figs. 6 and 7).

**Hypotension and bradycardia**

The incidences of hypotension and bradycardia were recorded in all of the included RCTs, but one [13]. There were 402 patients receiving dexmedetomidine (24 experienced hypotension and 19 had bradycardia) and 402 patients receiving tramadol (9 experienced hypotension and 2 had bradycardia).

Dexmedetomidine was associated with higher incidence of hypotension (RR = 2.50; 95%CI [1.24, 5.03], \( P = 0.01 \), \( I^2 = 0\% \)), and bradycardia (RR = 4.78; 95%CI [1.76, 13.00], \( P = 0.002 \), \( I^2 = 0\% \)). (Figs. 8 and 9).

**Sedation**

Ten studies reported the incidence of sedation which we defined as being drowsy and responding to verbal or physical stimuli [9–16, 19, 20]. The value of \( I^2 = 82\% \) indicated high heterogeneity. The incidence of sedation of dexmedetomidine was significantly higher than that of tramadol (RR = 2.48; 95%CI [1.32, 4.65], \( P = 0.005 \), \( I^2 = 82\% \)). (Fig. 10).

Sensitivity analysis was performed for the incidence of sedation by excluding single study sequentially, but no source of high heterogeneity was detected. There were no patients with over sedation reported in the included
studies. Over sedation was defined as no response to physical stimuli.

Publication bias
Figure 11 showed that no publication bias was detected for recurrent rate of shivering.

Discussion
In this meta-analysis, we compare the efficacy of intravenous dexmedetomidine and tramadol on the treatment of shivering after spinal anesthesia in adult patients. Dexmedetomidine is associated with higher effective rate of shivering control, shorter time to cease shivering, lesser recurrence of shivering, lower incidences of nausea and vomiting, higher incidences of hypotension, bradycardia and sedation than tramadol.

In this meta-analysis, dexmedetomidine has shorter time to cease shivering and a higher incidence of sedation than tramadol. But these outcomes have high heterogeneities, which are possibly associated with the following: 1) Inclusion criteria for shivering degree are different among the included studies, shivering degrees of 2 to 4 are included in 4 RCTs [14, 16, 18, 19] and shivering degrees of 3 or 4 in the other 9 RCTs [9–13, 15, 17, 20, 21]. 2) The types and doses of local anesthetics for spinal anesthesia are different among the studies; 3) The types and duration of the surgeries are different.

In this study, tramadol is associated with significantly higher incidences of nausea and vomiting than dexmedetomidine. Nausea and vomiting is very distressing for the patient. Moreover, vomiting may cause rare but
serious consequences, such as aspiration, esophageal rupture, subcutaneous emphysema or pneumothorax [22]. However, dexmedetomidine has significantly higher incidences of hypotension and bradycardia compared to tramadol. Dexmedetomidine has an inherent property of postsynaptic activation of alpha 2-adrenoceptors in the central nervous system to decrease heart rate and blood pressure. We can’t assess the clinically significance of hypotension and bradycardia, because of lack of research data.

Tramadol is a well-established agent in treatment of shivering. The mechanism of anti-shivering action of tramadol may be its opioid or serotonergic and noradrenergic activity or both [23–25]. Dexmedetomidine, an alpha-2 adrenoceptor agonist, has antihypertensive, sedative, analgesic and anti-shivering properties [26]. The anti-shivering effects of alpha adrenoceptor agonists are mediated by binding to alpha receptors that mediate the vasoconstriction. In addition, it has hypothalamic thermoregulatory effects of reducing the vasoconstriction and shivering thresholds [27]. It suggests that dexmedetomidine acts on the central thermoregulatory system rather than preventing shivering peripherally [28]. The effect of dexmedetomidine on treatment of shivering has been confirmed in the previous studies [29–31]. Dexmedetomidine and tramadol are not only effective for shivering treatment, but also effective for shivering prevention [32–34].

The sedation achieved is better in patients receiving dexmedetomidine than patients receiving tramadol. None of patients experiencing over sedation or respiratory depression is reported in the included studies [9–21]. Since the surgery is done under spinal anesthesia, the sedation seen with dexmedetomidine is beneficial for the surgeon, anesthetist as well as the patient, because it provides comfort and amnesia to the patient, cardiorespiratory stability and good surgical conditions during...
surgery. Therefore, dexmedetomidine may be a good choice for shivering control after spinal anesthesia because of its dual effects of anti-shivering and sedation.

There are two limitations in this study. First of all, there is a high heterogeneity regarding time to cease shivering and the incidence of sedation. Secondly, intravenous dexmedetomidine causes hypotension and bradycardia, but we haven’t analyzed whether it is clinically significant, due to lack of research data. Therefore, more RCTs are required for further study.

Conclusions
Dexmedetomidine is superior to tramadol for shivering treatment, due to higher effective rate of shivering control, earlier onset of action and lesser recurrence of shivering with higher incidence of sedation and lower incidences of nausea and vomiting. However, dexmedetomidine is also associated with higher incidences of hypotension and bradycardia than tramadol.

Abbreviations
MD: Mean difference; RR: Relative risk; CI: Confidence interval; RCT: Randomized controlled trials

Acknowledgements
Not applicable.

Authors’ contributions
NW and JW conceived the study, participated in the design, collected the data, performed statistical analyses, and drafted the manuscript. NW, JW and ZW participated in the design, collected the data, and helped to draft the manuscript. ZW and JL helped to perform statistical analyses and to revise it critically for important intellectual content. All authors read and approved the final manuscript.

Funding
The authors declare that they have no funding for this research reported.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
There is no conflict of interests to disclose. I hereby certify that this paper consists of original, unpublished work which is not under consideration for publication elsewhere. The abstract is not presented in any of conference proceedings. The authors declare that they have no competing interests.

Acknowledgements

Fig. 11  Funnel plot of recurrent rate of shivering

1. Shukla U, Malhotra K, Prabhakar T. A comparative study of the effect of clonidine and tramadol on post-spinal anaesthesia shivering. Indian J Anaesth. 2011;55:242–6.
2. Alfonsi P. Postanaesthetic shivering. Epidemiology, pathophysiology and approaches to prevention and management. Minerva Anestesiol. 2003;69:438–42.
3. Crowley LJ, Buggy DJ. Shivering and neuraxial anesthesia. Reg Anesth Pain Med. 2008;33:241–52.

References

Author details
1Department of Urology, The First Hospital of Jilin University, No.1 Xinmin Street, Changchun, Jilin 130021, China. 2Department of Taxation, School of Public Economics and Administration of Shanghai University of Finance and Economics, NO.777, Guoding Road, Yangpu District, Shanghai 200433, China. 3Department of Anesthesiology, The First Hospital of Jilin University, No.1 Xinmin Street, Changchun, Jilin 130021, China.

Received: 8 January 2020 Accepted: 23 April 2020

Published online: 04 May 2020
4. Giesbrecht GG, Sessler DI, Mekjavic IB, Schroeder M, Bristow GK. Treatment of mild immersion hypothermia by direct body-to-body contact. J Appl Physiol. 1994;76:2373–9.

5. Ciolfolo MJ, Clergue F, Devillers C, Ben Ammar M, Vlars P. Changes in ventilation, oxygen uptake, and carbon dioxide output during recovery from isoflurane anaesthesia. Anaesthesia. 1989;44:737–41.

6. Blaine Easley R, Brady KM, Tobias JD. Dexmedetomidine for the treatment of postanaesthesia shivering in children. Pediatric Anaesth. 2007;17:341–6.

7. Wrench UJ, Singh P, Dennis AR, Mahajan RP, Crossley AW. The minimum effective doses of pethidine and doxapram in the treatment of post-anaesthetic shivering. Anaesthesia. 1997;52:2–6.

8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

9. Kundra TS, Kuthiala G, Shrivastava A, Kaur P. A comparative study on the efficacy of dexmedetomidine and tramadol on post-spiroanal shivering. Saudi J Anaesth. 2017;11:28–31.

10. Mittal G, Gupta K, Katyal S, Kaushal S. Randomised double-blind comparative study of dexmedetomidine and tramadol for post-spinal anaesthesia shivering. Indian J Anaesth. 2014;58:257–62.

11. Verma A, Bhandari D, Dhande P, Jain S, Tidke S. Comparative evaluation of dexmedetomidine and tramadol for attenuation of post-Spinal anaesthesia shivering. J Clin Diagn Res. 2018;12:UC01–4.

12. Prasad P. Comparison of tramadol and dexmedetomidine for treatment of shivering during spinal anaesthesia in caesarean section. J Evolution Med Dent Sci. 2019;6:560–1.

13. Ramesh K, Bhushanam KN, Sharma BA, Kumar SSS. A clinical comparative study between intra venous dexmedetomidine and tramadol for control of post spinal anaesthesia shivering. J Dent Med Sci. 2019;18:26–31.

14. Singla A, Chaudhari M, Patel A. Efficacy and safety of tramadol and dexmedetomidine in treatment of shivering following spinal anaesthesia: a randomized controlled study. J Med Clin Res. 2015;7:20338–44.

15. Asim SA, Reddy AS, Reddy V, reddy M, Chandirakhan C. Randomised double-blind comparative study of tramadol and dexmedetomidine for post-spiroanal anaesthesia shivering. J Chalmeda Anand Rao Inst Med Sci. 2016;11:18–21.

16. Venkatraman R, Karthik K, Pushparani A, Mahalakshmi A. A prospective, randomized, double-blinded control study on comparison of tramadol, clonidine and dexmedetomidine for post spinal anaesthesia shivering. Rev Bras Anestesiol. 2016;68:42–8.

17. Kumar YD, Kumar TR, Sasi RK, Prachi P. A clinical comparative study of dexmedetomidine, clonidine and tramadol in post spinal shivering in lower limb and lower abdominal surgeries. J Dent Med Sci. 2016;15:50–4.

18. Verma NK, Kumar M. Comparison of clonidine, dexmedetomidine and tramadol for control of post spinal shivering: A randomized double blind clinical study. Int J Life Sci Res Res. 2016;2:658–64.

19. Keerthi P, Kannath SS. Comparative study of dexmedetomidine, butorphanol and tramadol for post-spinal anaesthesia shivering. Res J Pharmaceutical Biological Chemical Sci. 2017;8:1801–9.

20. Singh A, Gupta KK, Solanki SL, Kumar M. A prospective randomized double blind comparative study of clonidine, dexmedetomidine and tramadol for treatment of shivering under spinal anaesthesia. Ind J Public Health Res Dev. 2016;7:114–9.

21. Fern L, Mlsian K. Comparison of dexmedetomidine, pethidine and tramadol in the treatment of post-neuraxial anaesthesia shivering. South Afr J Anaesth Analg. 2015;21:21–6.

22. Apfel CC. Postoperative nausea and vomiting. Miller's Anaesthesia. 7th ed. New York: Churchill Livingstone; 2010.

23. Lee CR, McAvish D, Sorbin EM. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46:313–40.

24. Mathews S, Al Mulla A, Varghese PK, Radim K, Mumtaz S. Postanaesthetic shivering-a new look at tramadon. Anaesthesia. 2002;57:394–8.

25. Tsai YC, Chu KS. A comparison of tramadol, amitriptyline, and meperidine for postepidural anaesthetic shivering in parturients. Anesth Analg. 2001;93:288–92.

26. Grewal A. Dexmedetomidine: new avenues. J Anaesthesiol Clin Pharmacol. 2011;27:297–302.

27. Bajwa SJ, Bajwa SK, Kaur J, Singh G, Arora V, Gupta S, et al. Dexmedetomidine and clonidine in epidural anaesthesia: a comparative evaluation. Indian J Anaesth. 2011;55:116–21.